{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:02:00Z","timestamp":1794243720743,"version":"4.9.0"},"reference-count":37,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: CDK4\/6 inhibitors (CDK4\/6i) have revolutionized the treatment of hormone receptor-positive HER2 negative (HR(+)\/HER2(-)) breast cancer. Despite their efficacy, interstitial lung disease (ILD) remains a rare but potentially fatal adverse effect. This study aims to evaluate the incidence and clinical characteristics of ILD associated with CDK4\/6 inhibitors in breast cancer patients in Turkey. Materials and Methods: A retrospective multicenter analysis included 464 breast cancer patients treated with CDK4\/6 inhibitors between January 2017 and April 2024. Patients receiving ribociclib or palbociclib were evaluated for the development of ILD. Radiological assessments were performed to confirm ILD and exclude other conditions. Clinical characteristics, treatment regimens, and outcomes were analyzed. Results: ILD was identified in 10 patients (2.1%). The average age of the affected patients was 62.5 \u00b1 9.85 years. Hypersensitivity pneumonitis and nonspecific interstitial pneumonia (NSIP) were the most common radiological patterns. Palbociclib was implicated in six cases, while ribociclib was associated with four cases. Grade 3 pulmonary toxicity was observed in eight patients, and Grade 4 toxicity in two patients. One patient who was on palbociclib died due to ILD. No significant correlation was found between ILD and age, smoking status, lung metastases, or prior thoracic radiotherapy. Conclusions: The incidence of CDK4\/6 inhibitor-associated ILD in Turkish breast cancer patients appears higher than previously reported in clinical trials. More robust, long-term studies are necessary to identify potential risk factors and mitigate ILD-related mortality.<\/jats:p>","DOI":"10.3390\/medicina61030549","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T12:23:11Z","timestamp":1742473391000},"page":"549","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Incidence and Clinical Characteristics of Interstitial Lung Disease Associated with CDK4\/6 Inhibitors in Breast Cancer Patients: A Retrospective Multicenter Study"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9908-9284","authenticated-orcid":false,"given":"Nurullah","family":"\u0130lhan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Sancaktepe, \u015eehit Prof Dr. \u0130lhan Varank Training Research Hospital, Istanbul 34785, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4275-2414","authenticated-orcid":false,"given":"Akif","family":"Do\u011fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Sancaktepe, \u015eehit Prof Dr. \u0130lhan Varank Training Research Hospital, Istanbul 34785, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-3791-9157","authenticated-orcid":false,"given":"Hande Nur","family":"Er\u00f6lmez","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Health Science University, Sancaktepe, \u015eehit Prof Dr. \u0130lhan Varank Training Research Hospital, Istanbul 34785, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Atalah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Medeniyet University, Prof. Dr. S\u00fcleyman Yal\u00e7\u0131n City Hospital, Istanbul 34700, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5883-445X","authenticated-orcid":false,"given":"S\u00fcleyman","family":"Ba\u015f","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Health Science University, Sancaktepe, \u015eehit Prof Dr. \u0130lhan Varank Training Research Hospital, Istanbul 34785, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9404-3217","authenticated-orcid":false,"given":"Servan","family":"Yasar","sequence":"additional","affiliation":[{"name":"Department of Radiology, Health Science University, Sancaktepe, \u015eehit Prof Dr. \u0130lhan Varank Training Research Hospital, Istanbul 34785, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-4705","authenticated-orcid":false,"given":"Hatice","family":"Odaba\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Science University, Kartal Dr. L\u00fctfi K\u0131rdar City Hospital, Istanbul 34865, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"G\u00fcm\u00fc\u015f","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Medeniyet University, Prof. Dr. S\u00fcleyman Yal\u00e7\u0131n City Hospital, Istanbul 34700, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"World Health Organization (2025, March 08). Breast Cancer. 20 September 2024. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"ref_3","first-page":"2929","article-title":"Breast cancer intrinsic subtype classification, clinical use, and future trends","volume":"5","author":"Dai","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1309\/AJCPIV9IQ1MRQMOO","article-title":"Molecular pathology of breast cancer: What a pathologist needs to know","volume":"138","author":"Allison","year":"2012","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_5","first-page":"102489","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i): Mechanisms of resistance and where to find them","volume":"114","author":"Foffano","year":"2023","journal-title":"Cancer Treat. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Malumbres, M. (2014). Cyclin-dependent kinases. Genome Biol., 15.","DOI":"10.1186\/gb4184"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/45159","article-title":"Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration","volume":"402","author":"Patrick","year":"1999","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"10254","DOI":"10.1073\/pnas.170144197","article-title":"Cyclin-dependent kinases as a therapeutic target for stroke","volume":"97","author":"Osuga","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/scbi.1995.0009","article-title":"Cyclins, CDKs, and cancer","volume":"6","author":"Pines","year":"1995","journal-title":"Semin. Cancer Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: Positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kim, S., Leong, A., Kim, M., and Yang, H.W. (2022). CDK4\/6 Initiates Rb Inactivation and CDK2 Activity Coordinates Cell-Cycle Commitment and G1\/S Transition. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-20769-5"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/cncr.32931","article-title":"Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies","volume":"126","author":"Sharifi","year":"2020","journal-title":"Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: Patient-reported outcomes from the PALOMA-3 trial","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eabc1495","DOI":"10.1126\/science.abc1495","article-title":"CDK4, and CDK6 kinases: From basic science to cancer therapy","volume":"375","author":"Fassl","year":"2022","journal-title":"Science"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution\u2014A game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_17","first-page":"151228","article-title":"CDK4\/6 Inhibitors in the Treatment of Metastatic Breast Cancer: Focus on Toxicity and Safety","volume":"51","author":"Wekking","year":"2024","journal-title":"Semin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14737140.2019.1674651","article-title":"Can CDK4\/6 Inhibitors Cause Fatal Lung Injury?","volume":"19","author":"Jazieh","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Skeoch, S., Weatherley, N., Swift, A.J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J.M., Waterton, J.C., and Buch, M. (2018). Drug-induced interstitial lung disease: A systematic review. J. Clin. Med., 7.","DOI":"10.3390\/jcm7100356"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1513\/AnnalsATS.201801-067OC","article-title":"Heterogeneity in unclassifiable interstitial lung disease: A systematic review and meta-analysis","volume":"15","author":"Guler","year":"2018","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1200\/JCO.19.02318","article-title":"Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low\u2013expressing advanced breast cancer: Results from a phase Ib study","volume":"38","author":"Modi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: Past, present, and future","volume":"395","author":"Spring","year":"2020","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e749","DOI":"10.1002\/onco.13684","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer: Updated analysis with up to 5 years of follow-up","volume":"26","author":"Finn","year":"2021","journal-title":"Oncologist"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2021","journal-title":"Oncologist"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: A pharmacovigilance assessment","volume":"186","author":"Raschi","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.breast.2022.02.011","article-title":"Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4\/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Zhang","year":"2022","journal-title":"Breast"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s12282-020-01207-8","article-title":"Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan","volume":"28","author":"Chen","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.annonc.2021.03.058","article-title":"44O Characterization of venous thromboembolic events (VTE), elevated aminotransferases (EAT), and interstitial lung disease (ILD) in monarchE","volume":"32","author":"Toi","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_31","first-page":"14799731241291538","article-title":"Smoking-related interstitial lung disease: A narrative review","volume":"21","author":"Casal","year":"2024","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.36401\/JIPO-24-12","article-title":"Updates in drug-related pneumonitis due to targeted oncologic therapies","volume":"7","author":"Chan","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/10781552231163121","article-title":"CDK4\/6 inhibitors in metastatic breast cancer: A comparison of toxicity and efficacy across agents in a real-world dataset","volume":"29","author":"Buller","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.breast.2020.10.007","article-title":"Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia","volume":"54","author":"Moreno","year":"2020","journal-title":"Breast"},{"key":"ref_35","unstructured":"(2023, March 16). Rechallenge with a Different CDK 4\/6 Inhibitor After Ribociclib-Induced Hepatotoxicity. Available online: https:\/\/www.bib.irb.hr\/1147359."},{"key":"ref_36","first-page":"679","article-title":"Incidence of interstitial lung disease in patients with breast cancer: A nationwide database study in Japan","volume":"19","author":"Nishijima","year":"2023","journal-title":"Future Oncol."},{"key":"ref_37","first-page":"264","article-title":"Cancer therapy-related interstitial lung disease","volume":"138","author":"Zhou","year":"2025","journal-title":"Chin. Med. J."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/549\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:57:21Z","timestamp":1760029041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/3\/549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["medicina61030549"],"URL":"https:\/\/doi.org\/10.3390\/medicina61030549","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]}}}